NasdaqCM - Delayed Quote • USD
Soleno Therapeutics, Inc. (SLNO)
At close: April 25 at 4:00 PM EDT
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 6 | 6 | 6 | 6 |
| Avg. Estimate | -0.37 | -0.37 | -1.56 | -0.75 |
| Low Estimate | -0.66 | -0.72 | -2.9 | -1.52 |
| High Estimate | -0.27 | -0.27 | -1.06 | 0.13 |
| Year Ago EPS | -0.88 | -0.81 | -2.36 | -1.56 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 6 | 6 | 6 | 6 |
| Avg. Estimate | -- | -- | -- | 44.94M |
| Low Estimate | -- | -- | -- | 17.36M |
| High Estimate | -- | -- | -- | 94M |
| Year Ago Sales | -- | -- | -- | -- |
| Sales Growth (year/est) | -- | -- | -- | -- |
Earnings History
| CURRENCY IN USD | 3/31/2023 | 6/30/2023 | 9/30/2023 | 12/31/2023 |
|---|---|---|---|---|
| EPS Est. | -0.72 | -0.83 | -0.58 | -0.27 |
| EPS Actual | -0.88 | -0.81 | -0.95 | -0.33 |
| Difference | -0.16 | 0.02 | -0.37 | -0.06 |
| Surprise % | -22.20% | 2.40% | -63.80% | -22.20% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | -0.37 | -0.37 | -1.56 | -0.75 |
| 7 Days Ago | -0.37 | -0.37 | -1.56 | -0.75 |
| 30 Days Ago | -0.37 | -0.37 | -1.56 | -0.75 |
| 60 Days Ago | -0.29 | -0.29 | -1.15 | -0.28 |
| 90 Days Ago | -0.28 | -0.28 | -1.11 | 0 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | -- | -- | -- | -- |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| CURRENCY IN USD | SLNO | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | 58.00% | -- | -- | 2.60% |
| Next Qtr. | 54.30% | -- | -- | 13.40% |
| Current Year | 33.90% | -- | -- | 5.20% |
| Next Year | 51.90% | -- | -- | 13.30% |
| Next 5 Years (per annum) | 15.00% | -- | -- | 11.11% |
| Past 5 Years (per annum) | -- | -- | -- | -- |
Research Analysis
Upgrades & Downgrades
| Initiated | Piper Sandler: Overweight | 2/5/2024 |
| Initiated | Stifel: Buy | 1/23/2024 |
| Maintains | Oppenheimer: Outperform to Outperform | 1/2/2024 |
| Maintains | Cantor Fitzgerald: Overweight to Overweight | 9/26/2023 |
| Maintains | Oppenheimer: Outperform to Outperform | 9/15/2023 |
| Reiterates | Cantor Fitzgerald: Overweight to Overweight | 8/31/2023 |
Related Tickers
MLTX MoonLake Immunotherapeutics
42.25
-0.42%
DNTH Dianthus Therapeutics, Inc.
20.99
-1.55%
VERA Vera Therapeutics, Inc.
38.69
-3.15%
SYRE Spyre Therapeutics, Inc.
32.47
-1.58%
SWTX SpringWorks Therapeutics, Inc.
44.20
+1.89%
LBPH Longboard Pharmaceuticals, Inc.
19.25
-2.53%
COGT Cogent Biosciences, Inc.
6.01
-8.10%
GPCR Structure Therapeutics Inc.
38.98
+7.00%
DYN Dyne Therapeutics, Inc.
23.70
-5.14%
CGEM Cullinan Therapeutics, Inc.
19.25
+1.91%